|

Study to ONO-4538 in Patients With Rhabdoid Tumor

RECRUITINGPhase 2Sponsored by Ono Pharmaceutical Co. Ltd
Actively Recruiting
PhasePhase 2
SponsorOno Pharmaceutical Co. Ltd
Started2024-11-25
Est. completion2029-01-31
Eligibility
Age1 Year+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06622941

Summary

Investigate the efficacy and safety of ONO-4538 for the treatment of rhabdoid Tumors

Eligibility

Age: 1 Year+Healthy volunteers accepted
Inclusion Criteria:

1. Gender: Not specified
2. Age (at the time of consent): 1 year or older
3. Patients who are refractory or intolerant to one or more regimens of chemotherapy for rhabdoid Tumors
4. Patients with advanced or recurrent rhabdoid Tumors not eligible for curative resection

Exclusion Criteria:

1. Patients with a history of active concurrent malignancy or complications
2. Patients with spinal lesions expected to require radiation therapy or surgical intervention during the trial period
3. Patients with concomitant central nervous system disorders other than AT/RT that are inadequately controlled or may lead to discontinuation of the investigational drug

Conditions2

CancerRhabdoid Tumor

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.